Executive Director, Drug Metabolism
Gilead Sciences
Bernard Murray is an Executive Director in the Drug Metabolism Department and head of the In Vitro Drug Metabolism group at Gilead Sciences. He specialises in enzymology and particularly in its applications in human PK prediction and understanding drug interaction liabilities. He obtained his BSc in Pharmacology from Liverpool University and his PhD from the Royal Postgraduate Medical School in London. He was previously a researcher in London, at NCI/NIH and UCSF, and a Scientific Leader at Abbott Laboratories. He has more than 60 publications, including reviews and book chapters.